Answers are grounded in this paper and cite their sources.
Nebulized ensifentrine offers a novel non-steroidal anti-inflammatory and bronchodilator treatment added to existing LAMA or LABA + ICS treatment options in patients with moderate to severe, symptomatic COPD.
No takes yet. Share an insight, caveat, or question.
Dransfield et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: